Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D
Sanofi (SNY) Q2 sales hit $13.48B, beating estimates driven by Dupixent's 37.6% surge. Full details on earnings and 2026 outlook.
Sanofi made more money than expected this quarter because one of their medicines (Dupixent) sold really well. But the company admitted they sometimes make choices too quickly in creating new drugs, and they're going to be more careful going forward.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.